Buminate Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to established clinical use of albumin, growth in surgical procedures, expansion of critical care units, proven safety profile, reliance on plasma derived therapies.

The growth in the forecast period can be attributed to increase in trauma cases, rising surgical interventions, expansion of icu infrastructure, demand for rapid volume replacement, improved plasma fractionation capacity. Major trends in the forecast period include continued use of albumin in critical care, rising demand in trauma and burn management, expansion of surgical volume support therapies, preference for plasma derived proteins, growth in intensive care admissions.

The increasing prevalence of liver diseases is expected to drive the growth of the buminate market in the coming years. Liver diseases encompass a wide range of conditions that impair liver function, including cirrhosis, hepatitis, fatty liver disease, and liver cancer, often caused by infections, toxins, genetics, or chronic alcohol use. The rise in liver diseases is largely attributed to unhealthy lifestyle and dietary habits, as excessive alcohol intake, poor diet, and obesity contribute to liver damage and fat accumulation. Buminate, a human albumin solution, helps manage liver diseases by restoring and maintaining blood volume and osmotic pressure in patients with conditions such as cirrhosis or liver failure, improving circulation, supporting proper fluid balance, and reducing the risk of complications like edema and ascites. For example, in April 2025, the Centers for Disease Control and Prevention (CDC), a US-based federal agency, reported 17,650 new chronic hepatitis B cases across 44 states and the District of Columbia in 2023, representing a prevalence rate of 6.1 cases per 100,000 people. Therefore, the increasing prevalence of liver diseases is driving growth in the buminate market.

The growing number of clinical trials is also expected to propel the growth of the buminate market. Clinical trials are research studies involving human participants to assess the safety, efficacy, and effectiveness of medical treatments, interventions, drugs, or devices. The rise in clinical trials is fueled by advancements in medical research and technology, the increasing incidence of chronic and complex diseases, and an aging global population seeking new treatments. Clinical trials benefit Buminate by providing essential data on its safety, efficacy, and potential new applications, supporting approval and adoption in various medical settings, enhancing physician confidence, expanding its use across conditions, and ultimately contributing to higher market demand and growth. For example, in February 2024, ClinicalTrials.gov, a US-based government web resource, reported that clinical trial result publications increased from 4,024 in 2022 to 5,063 in 2023. Therefore, the rise in clinical trials is driving the growth of the buminate market.

Rising healthcare expenditure is also expected to support the growth of the buminate market. Healthcare expenditure refers to the total resources spent on health services and related activities over a given period, typically measured annually. The increase in healthcare spending is driven by factors such as an aging population, chronic diseases, rising service prices, greater demand, technological advancements, higher drug costs, the impact of COVID-19, medical inflation, and income disparities. Buminate benefits from this growth in expenditure, as increased investment in healthcare infrastructure and services drives demand for effective treatments like Buminate, particularly for conditions such as hypoalbuminemia and trauma, leading to wider adoption, improved accessibility, and steady revenue streams for manufacturers and healthcare providers. For instance, in May 2024, the Office for National Statistics, a UK-based government department, reported that healthcare spending in the UK increased by 5.6% between 2022 and 2023, compared with 0.9% growth in 2022. The total healthcare expenditure in the UK was approximately $317.63 billion (£292 billion) in 2023. Therefore, rising healthcare expenditure is driving the growth of the buminate market.

Major companies operating in the buminate market are Grifols S.A.

North America was the largest region in the buminate market in 2025. The regions covered in the buminate market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the buminate market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the buminate market by raising costs associated with plasma collection, fractionation equipment, and sterile packaging materials. These impacts are more significant in regions dependent on imported plasma derivatives such as asia pacific. Hospital procurement budgets have faced pricing pressure for albumin products. However, tariffs have driven investments in domestic plasma processing. This strengthens long term supply resilience for critical care therapies.

The buminate market research report is one of a series of new reports that provides buminate market statistics, including buminate industry global market size, regional shares, competitors with a buminate market share, detailed buminate market segments, market trends and opportunities, and any further data you may need to thrive in the buminate industry. This buminate market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Buminate is a brand of human albumin solution, a protein derived from human plasma. It is primarily used to restore or maintain circulating blood volume in patients experiencing shock, burns, trauma, or undergoing surgery. Buminate works by increasing the osmotic pressure of the blood, drawing fluid into the bloodstream to enhance circulation and tissue perfusion.

The main indications for buminate are hypoproteinemia, burn treatment, and cardiopulmonary bypass surgery. Hypoproteinemia is a condition characterized by low levels of proteins in the blood, particularly albumin, which can result from malnutrition, liver disease, kidney disease, or severe burns. Buminate is distributed through hospital pharmacies, outpatient clinics, and specialty pharmacies, and is utilized by hospitals, clinics, ambulatory care centers, and home care settings.

The buminate market consists of sales of buminate 25% solution, pre-filled syringes and multi-dose vials. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.